Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508561 | 1.00 | TP53 (0.33) | TP53GRIA1PPARAFUT7EPHX1 | |
| SCHEMBL28315394 | 0.84 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL2597785 | 0.84 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL28350946 | 0.84 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL27761167 | 0.84 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL28611800 | 0.84 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL31348971 | 0.77 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL31348943 | 0.77 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL31348932 | 0.77 | PPARA (0.44) | PPARAEPHX1 | |
| SCHEMBL28325394 | 0.76 | CA1 (0.39) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007622-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | UNIV FLORIDA STATE RES FOUND (US) | 2026-01-08 | — | — | US | claimed |
| US-20250041253-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2025-02-06 | — | — | US | claimed |
| US-12161611-B2 | Niclosamide formulations and methods of use | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-12-10 | — | — | US | claimed |
| US-20230390225-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-12-07 | — | — | US | claimed |
| US-11771668-B2 | Niclosamide formulations and methods of use | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | claimed |
| EP-3320921-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2022-01-05 | — | — | EP | claimed |
| US-20210308079-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2021-10-07 | — | — | US | claimed |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2018-06-07 | — | — | US | claimed |
| EP-3320921-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Ala Wai Pharma, Inc. (US) | 2018-05-16 | — | — | EP | claimed |
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2017-06-08 | — | — | US | claimed |
| US-9579383-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2017-02-28 | — | — | US | claimed |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2014-03-13 | — | — | US | claimed |
| US-8609139-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | UNIVERSITY OF HAWAII | 2011-08-25 | — | — | US | claimed |
| EP-2217216-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Scolr Pharma, Inc. (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009061805-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SCOLR PHARMA, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| US-12533416-B2 | Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents | ID CARE UG (haftungsbeschränkt) (DE) | 2026-01-27 | — | — | US | disclosed |
| US-20260007622-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | UNIV FLORIDA STATE RES FOUND (US) | 2026-01-08 | — | — | US | disclosed |
| EP-2217216-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Scolr Pharma, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061805-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SCOLR PHARMA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041253-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, NCSTN, PRSS2 | TP53 1645/4885GRIA1 2311/4885PPARA 1104/4885 |
| US-20230390225-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, NCSTN, PRSS2 | TP53 1645/4885GRIA1 2311/4885PPARA 1104/4885 |
| US-20260007622-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, PKD2, DSP | TP53 1454/4885GRIA1 3689/4885PPARA 1821/4885 |
| US-20210308079-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, NCSTN, PRSS2 | TP53 1645/4885GRIA1 2311/4885PPARA 1104/4885 |
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | TP53 2031/4885GRIA1 4244/4885PPARA 794/4885 |
| US-11771668-B2 | Niclosamide formulations and methods of use | TMPRSS2, NCSTN, PRSS2 | TP53 1645/4885GRIA1 2311/4885PPARA 1104/4885 |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | TP53 2031/4885GRIA1 4244/4885PPARA 794/4885 |
| US-12161611-B2 | Niclosamide formulations and methods of use | TMPRSS2, NCSTN, PRSS2 | TP53 1645/4885GRIA1 2311/4885PPARA 1104/4885 |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | TP53 2031/4885GRIA1 4244/4885PPARA 794/4885 |
| US-12533416-B2 | Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents | CYP8B1, CEL, KLK8 | TP53 1590/4885GRIA1 4743/4885PPARA 749/4885 |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | TP53 2031/4885GRIA1 4244/4885PPARA 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.